{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:46:36Z","timestamp":1792802796548,"version":"4.5.0"},"reference-count":202,"publisher":"Elsevier","isbn-type":[{"value":"9780443158223","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005637","name":"MDC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.apcsb.2022.11.008","type":"book-chapter","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T18:28:52Z","timestamp":1675708132000},"page":"125-177","source":"Crossref","is-referenced-by-count":58,"title":["CDK regulators\u2014Cell cycle progression or apoptosis\u2014Scenarios in normal cells and cancerous cells"],"prefix":"10.1016","author":[{"family":"Nilmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D'costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Bothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumik","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Udhaya Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gnanasambandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"George Priya Doss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.apcsb.2022.11.008_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2018.07.008","article-title":"Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein","volume":"69","author":"Abbastabar","year":"2018","journal-title":"DNA Repair"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2018-04-845420","article-title":"Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment","volume":"133","author":"Abdul-Aziz","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0020","doi-asserted-by":"crossref","first-page":"E412","DOI":"10.3390\/molecules26020412","article-title":"A new CDK2 inhibitor with 3-hydrazonoindolin-2-one scaffold endowed with anti-breast cancer activity: Design, synthesis, biological evaluation, and in silico insights","volume":"26","author":"Al-Sanea","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"11","key":"10.1016\/bs.apcsb.2022.11.008_bb0025","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMcibr1808772","article-title":"Cyclin-dependent kinase 12, immunity, and prostate cancer","volume":"379","author":"Antonarakis","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"40","key":"10.1016\/bs.apcsb.2022.11.008_bb0035","doi-asserted-by":"crossref","first-page":"26259","DOI":"10.18632\/oncotarget.25447","article-title":"Role of p27Kip1 as a transcriptional regulator","volume":"9","author":"Bachs","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0040","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1128\/MCB.01363-13","article-title":"P19Ink4d is a tumor suppressor and controls pituitary anterior lobe cell proliferation","volume":"34","author":"Bai","year":"2014","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0045","article-title":"New advances in supportive care: Chemoprotective agents as novel opportunities in geriatric oncology","author":"Balducci","year":"2022","journal-title":"Current Oncology Reports"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0050","series-title":"Cell aging: Molecular mechanisms and implications for disease","author":"Behl","year":"2014"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0055","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.canlet.2017.06.031","article-title":"p27Kip1 and human cancers: A reappraisal of a still enigmatic protein","volume":"403","author":"Bencivenga","year":"2017","journal-title":"Cancer Letters"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0060","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/med.21856","article-title":"Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline","volume":"42","author":"Bhurta","year":"2022","journal-title":"Medicinal Research Reviews"},{"issue":"27","key":"10.1016\/bs.apcsb.2022.11.008_bb0065","doi-asserted-by":"crossref","first-page":"44266","DOI":"10.18632\/oncotarget.17863","article-title":"Leflunomide\/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication","volume":"8","author":"Bilger","year":"2017","journal-title":"Oncotarget"},{"issue":"26","key":"10.1016\/bs.apcsb.2022.11.008_bb0070","doi-asserted-by":"crossref","first-page":"42343","DOI":"10.18632\/oncotarget.16216","article-title":"Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4\/6 for use as an oral antineoplastic in patients with CDK4\/6 sensitive tumors","volume":"8","author":"Bisi","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0075","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/1535-7163.MCT-15-0775","article-title":"Preclinical characterization of G1T28: A novel CDK4\/6 inhibitor for reduction of chemotherapy-induced myelosuppression","volume":"15","author":"Bisi","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0080","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543784.2013.789859","article-title":"Cyclin-dependent kinase inhibitor therapy for hematologic malignancies","volume":"22","author":"Bose","year":"2013","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"21","key":"10.1016\/bs.apcsb.2022.11.008_bb0085","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1242\/jcs.205427","article-title":"The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain","volume":"130","author":"Bosnakovski","year":"2017","journal-title":"Journal of Cell Science"},{"issue":"16","key":"10.1016\/bs.apcsb.2022.11.008_bb0090","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1021\/jm9006559","article-title":"Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor","volume":"52","author":"Brasca","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tcb.2021.01.010","article-title":"New insights into CDK regulators: Novel opportunities for cancer therapy","volume":"31","author":"Bury","year":"2021","journal-title":"Trends in Cell Biology"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0100","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.celrep.2019.09.087","article-title":"NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 inhibitor","volume":"29","author":"Bury","year":"2019","journal-title":"Cell Reports"},{"issue":"19","key":"10.1016\/bs.apcsb.2022.11.008_bb0105","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41388-018-0659-4","article-title":"Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments","volume":"38","author":"Carrero","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.837835","article-title":"Rational combinations of targeted therapy and immune checkpoint inhibitors in head and neck cancers","volume":"12","author":"Chai","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0115","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41375-022-01553-w","article-title":"Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells","volume":"36","author":"Chen","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.biopha.2018.08.116","article-title":"An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers","volume":"107","author":"Chohan","year":"2018","journal-title":"Biomedicine & Pharmacotherapy=Biomedecine & Pharmacotherapie"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jcp.25421","article-title":"Flavopiridol: An old drug with new perspectives? Implication for development of new drugs","volume":"232","author":"Cimini","year":"2017","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0130","series-title":"Cancer: The enemy from within","first-page":"25","article-title":"Cancer initiation, promotion, and progression and the acquisition of key behavioral traits","author":"Compton","year":"2020"},{"issue":"1\u20132","key":"10.1016\/bs.apcsb.2022.11.008_bb0135","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mce.2013.09.005","article-title":"Genetic and epigenetic changes in sporadic endocrine tumors: Parathyroid tumors","volume":"386","author":"Costa-Guda","year":"2014","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.584590","article-title":"Functional versatility of the CDK inhibitor p57Kip2","volume":"8","author":"Creff","year":"2020","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0145","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nchembio.1952","article-title":"A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease","volume":"11","author":"Dale","year":"2015","journal-title":"Nature Chemical Biology"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41418-020-00648-0","article-title":"Ubiquitin signaling in cell cycle control and tumorigenesis","volume":"28","author":"Dang","year":"2021","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fcell.2018.00171","article-title":"Molecular and in vivo functions of the CDK8 and CDK19 kinase modules","volume":"6","author":"Dannappel","year":"2018","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0160","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3892\/ol.2015.3726","article-title":"P27Kip1 expression as a prognostic marker for squamous cell carcinoma of the head and neck","volume":"10","author":"De Almeida","year":"2015","journal-title":"Oncology Letters"},{"issue":"6\u20137","key":"10.1016\/bs.apcsb.2022.11.008_bb0165","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/15384101.2019.1593708","article-title":"Ribosomal protein RPL22\/eL22 regulates the cell cycle by acting as an inhibitor of the CDK4-cyclin D complex","volume":"18","author":"Del Toro","year":"2019","journal-title":"Cell Cycle (Georgetown, Texas)"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0170","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.biopha.2017.05.030","article-title":"Upregulation of CCAT2 promotes cell proliferation by repressing the P15 in breast cancer","volume":"91","author":"Deng","year":"2017","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.trecan.2019.03.001","article-title":"DUX4 pathological expression: Causes and consequences in cancer","volume":"5","author":"Dib","year":"2019","journal-title":"Trends in Cancer"},{"issue":"26","key":"10.1016\/bs.apcsb.2022.11.008_bb0180","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/onc.2016.506","article-title":"CyclinD-CDK4\/6 complexes phosphorylate CDC25A and regulate its stability","volume":"36","author":"Dozier","year":"2017","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/bs.apcsb.2022.11.008_bb0185","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1042\/BCJ20180465","article-title":"HDAC1 overexpression enhances \u03b2-cell proliferation by down-regulating Cdkn1b\/p27","volume":"475","author":"Draney","year":"2018","journal-title":"The Biochemical Journal"},{"issue":"25","key":"10.1016\/bs.apcsb.2022.11.008_bb0190","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1093\/hmg\/ddu406","article-title":"P19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas","volume":"23","author":"Dreidax","year":"2014","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0195","doi-asserted-by":"crossref","first-page":"111694","DOI":"10.1016\/j.mrfmmm.2020.111694","article-title":"WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry","volume":"819\u2013820","author":"Elb\u00e6k","year":"2020","journal-title":"Mutation Research"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0200","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: P53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death and Differentiation"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0205","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/cancers14020293","article-title":"The renaissance of cyclin dependent kinase inhibitors","volume":"14","author":"Ettl","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0210","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/s41598-018-37917-5","article-title":"Evolutionary approach of intrinsically disordered CIP\/KIP proteins","volume":"9","author":"Fahmi","year":"2019","journal-title":"Scientific Reports"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108898","article-title":"An interdependent network of functional enhancers regulates transcription and EZH2 loading at the INK4a\/ARF locus","volume":"34","author":"Farooq","year":"2021","journal-title":"Cell Reports"},{"issue":"6577","key":"10.1016\/bs.apcsb.2022.11.008_bb0220","doi-asserted-by":"crossref","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: From basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science (New York, N.Y.)"},{"issue":"10","key":"10.1016\/bs.apcsb.2022.11.008_bb0225","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4161\/cbt.25966","article-title":"P19(INK4d) mRNA and protein expression as new prognostic factors in ovarian cancer patients","volume":"14","author":"Felisiak-Golabek","year":"2013","journal-title":"Cancer Biology & Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): A randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"The Lancet. Oncology"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0235","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2174\/0929867003374048","article-title":"Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics","volume":"7","author":"Fischer","year":"2000","journal-title":"Current Medicinal Chemistry"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0240","first-page":"1016","article-title":"Revisiting the hallmarks of cancer","volume":"7","author":"Fouad","year":"2017","journal-title":"American Journal of Cancer Research"},{"issue":"16","key":"10.1016\/bs.apcsb.2022.11.008_bb0245","doi-asserted-by":"crossref","first-page":"22174","DOI":"10.18632\/oncotarget.7907","article-title":"Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer","volume":"7","author":"Francis","year":"2016","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/bs.apcsb.2022.11.008_bb0250","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","article-title":"Discovery of PF-06873600, a CDK2\/4\/6 inhibitor for the treatment of cancer","volume":"64","author":"Freeman-Cook","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13059-018-1401-9","article-title":"Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability","volume":"19","author":"Galanos","year":"2018","journal-title":"Genome Biology"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0260","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1476-4598-12-152","article-title":"Tumor glycolysis as a target for cancer therapy: Progress and prospects","volume":"12","author":"Ganapathy-Kanniappan","year":"2013","journal-title":"Molecular Cancer"},{"issue":"11","key":"10.1016\/bs.apcsb.2022.11.008_bb0265","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/emboj.2012.94","article-title":"Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion","volume":"31","author":"Ganuza","year":"2012","journal-title":"The EMBO Journal"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0270","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13287-017-0499-0","article-title":"Effects of mesenchymal stem cells from human induced pluripotent stem cells on differentiation, maturation, and function of dendritic cells","volume":"8","author":"Gao","year":"2017","journal-title":"Stem Cell Research & Therapy"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0275","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.3390\/genes10030244","article-title":"MYC oncogene contributions to release of cell cycle brakes","volume":"10","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Genes"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0280","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.molmed.2017.02.001","article-title":"p21: A two-faced genome guardian","volume":"23","author":"Georgakilas","year":"2017","journal-title":"Trends in Molecular Medicine"},{"issue":"13","key":"10.1016\/bs.apcsb.2022.11.008_bb0285","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2016-10-748210","article-title":"Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"129","author":"Ghia","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.apcsb.2022.11.008_bb0290","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 inhibition in cancer: Beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends in Cell Biology"},{"issue":"7668","key":"10.1016\/bs.apcsb.2022.11.008_bb0295","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0300","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/leu.2011.218","article-title":"TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties","volume":"26","author":"Goh","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0305","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317705336","article-title":"High expression of long non-coding RNA ZEB1-AS1 promotes colorectal cancer cell proliferation partially by suppressing p15 expression","volume":"39","author":"Gong","year":"2017","journal-title":"Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0310","article-title":"Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: More than CDK4\/6 inhibition","volume":"1\u201312","author":"Guo","year":"2022","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treatment Reviews"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0320","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3892\/ol.2017.5906","article-title":"New role of human ribosomal protein S3: Regulation of cell cycle via phosphorylation by cyclin-dependent kinase 2","volume":"13","author":"Han","year":"2017","journal-title":"Oncology Letters"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb984","doi-asserted-by":"crossref","first-page":"746385","DOI":"10.3389\/fphar.2021.746385","article-title":"Therapeutic potential of the cyclin-dependent kinase inhibitor flavopiridol on c-Myc overexpressing esophageal cancer","volume":"12","author":"Hassan","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"22","key":"10.1016\/bs.apcsb.2022.11.008_bb0325","first-page":"368","article-title":"Biological characterization of soft tissue sarcomas","volume":"3","author":"Hayashi","year":"2015","journal-title":"Annals of Translational Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0330","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/nano11030772","article-title":"Peptide-functionalized nanoparticles-encapsulated cyclin-dependent kinases inhibitor seliciclib in transferrin receptor overexpressed cancer cells","volume":"11","author":"He","year":"2021","journal-title":"Nanomaterials (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0335","first-page":"10","article-title":"Epigenetics of B-ALL","volume":"45","author":"Helmer","year":"2019","journal-title":"Journal of the Association of Genetic Technologists"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hern\u00e1ndez Borrero","year":"2021","journal-title":"Biochimica Et Biophysica Acta. Reviews on Cancer"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0345","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.stemcr.2014.10.005","article-title":"P19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging","volume":"3","author":"Hilpert","year":"2014","journal-title":"Stem Cell Reports"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0350","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1172\/JCI94586","article-title":"Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression","volume":"128","author":"Hossain","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"issue":"8","key":"10.1016\/bs.apcsb.2022.11.008_bb0355","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41419-018-0823-3","article-title":"Suppression of AURKA alleviates p27 inhibition on Bax cleavage and induces more intensive apoptosis in gastric cancer","volume":"9","author":"Hou","year":"2018","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0360","doi-asserted-by":"crossref","first-page":"zcab051","DOI":"10.1093\/narcan\/zcab051","article-title":"A comprehensive framework for analysis of micro RNA sequencing data in metastatic colorectal cancer","volume":"4","author":"H\u00f8ye","year":"2022","journal-title":"NAR Cancer"},{"issue":"13","key":"10.1016\/bs.apcsb.2022.11.008_bb0365","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","article-title":"Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7","volume":"79","author":"Hu","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107817","article-title":"Cellular senescence and hematological malignancies: From pathogenesis to therapeutics","volume":"223","author":"Hu","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0375","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1039\/D2MD00040G","article-title":"CDK9 inhibitors in cancer research","volume":"13","author":"Huang","year":"2022","journal-title":"RSC Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2012.44","article-title":"The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate","volume":"3","author":"Humeniuk","year":"2013","journal-title":"Blood Cancer Journal"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0385","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tibs.2018.12.007","article-title":"Interconnection between metabolism and cell cycle in cancer","volume":"44","author":"Icard","year":"2019","journal-title":"Trends in Biochemical Sciences"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0390","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.tranon.2019.08.010","article-title":"Indirubin 3\u2019-oxime inhibits migration, invasion, and metastasis in vivo in mice bearing spontaneously occurring pancreatic cancer via blocking the RAF\/ERK, AKT, and SAPK\/JNK pathways","volume":"12","author":"Ichimaru","year":"2019","journal-title":"Translational Oncology"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0395","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41598-020-58629-9","article-title":"Role of the imprinted allele of the Cdkn1c gene in mouse neocortical development","volume":"10","author":"Imaizumi","year":"2020","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0400","doi-asserted-by":"crossref","first-page":"18236","DOI":"10.1038\/s41598-021-97703-8","article-title":"P16INK4A expression might be associated with a favorable prognosis for cervical adenocarcinoma via dysregulation of the RB pathway","volume":"11","author":"Ishikawa","year":"2021","journal-title":"Scientific Reports"},{"issue":"10","key":"10.1016\/bs.apcsb.2022.11.008_bb0405","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s12276-020-00508-4","article-title":"Regulation of cell cycle drivers by Cullin-RING ubiquitin ligases","volume":"52","author":"Jang","year":"2020","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0410","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22207","article-title":"P27Kip1 promotes invadopodia turnover and invasion through the regulation of the PAK1\/Cortactin pathway","volume":"6","author":"Jeannot","year":"2017","journal-title":"eLife"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0415","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7868\/S0016675816010070","article-title":"A comparative analysis of methylation status of tumor suppressor genes in paired biopsy and serum samples from cervical cancer patients among North Indian population","volume":"52","author":"Jha","year":"2016","journal-title":"Genetika"},{"issue":"9","key":"10.1016\/bs.apcsb.2022.11.008_bb0420","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0425","first-page":"703","article-title":"Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS-032, on cervical cancer","volume":"53","author":"Kang","year":"2018","journal-title":"International Journal of Oncology"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0430","doi-asserted-by":"crossref","first-page":"E1157","DOI":"10.3390\/cancers12051157","article-title":"Extracellular vesicle delivery of TRAIL eradicates resistant tumor growth in combination with CDK inhibition by dinaciclib","volume":"12","author":"Ke","year":"2020","journal-title":"Cancers"},{"issue":"13_Supplement","key":"10.1016\/bs.apcsb.2022.11.008_bb0435","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1158\/1538-7445.AM2017-5133","article-title":"Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib","volume":"77","author":"Kim","year":"2017","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0440","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.leukres.2012.12.017","article-title":"5\u2019-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells","volume":"37","author":"Kim","year":"2013","journal-title":"Leukemia Research"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0445","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/acsmedchemlett.5b00278","article-title":"Development of a potent, specific CDK8 kinase inhibitor which phenocopies CDK8\/19 knockout cells","volume":"7","author":"Koehler","year":"2016","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0450","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0455","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s12094-020-02479-4","article-title":"Expression of p27 and p16 and their clinical significance in gastric cancer","volume":"23","author":"Kumari","year":"2021","journal-title":"Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"},{"issue":"7511","key":"10.1016\/bs.apcsb.2022.11.008_bb0460","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0465","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.seminoncol.2018.03.006","article-title":"CDK4\/6 Inhibition as a therapeutic strategy in breast cancer: Palbociclib, ribociclib, and abemaciclib","volume":"44","author":"Laderian","year":"2017","journal-title":"Seminars in Oncology"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0470","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1541-7786.MCR-13-0350","article-title":"The molecular balancing act of p16(INK4a) in cancer and aging","volume":"12","author":"LaPak","year":"2014","journal-title":"Molecular Cancer Research: MCR"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165715","article-title":"Cell cycle regulators in cancer cell metabolism","volume":"1866","author":"Leal-Esteban","year":"2020","journal-title":"Biochimica Et Biophysica Acta. Molecular Basis of Disease"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0480","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201800183","article-title":"Ribosomal proteins control tumor suppressor pathways in response to nucleolar stress","volume":"41","author":"Lessard","year":"2019","journal-title":"BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb981","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0485","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","article-title":"INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0490","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2020.09.011","article-title":"CDK12\/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer","volume":"495","author":"Li","year":"2020","journal-title":"Cancer Letters"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232068","article-title":"Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor","volume":"15","author":"Lim","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058227","article-title":"Polypyrimidine tract-binding protein induces p19(Ink4d) expression and inhibits the proliferation of H1299 cells","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"issue":"13_Supplement","key":"10.1016\/bs.apcsb.2022.11.008_bb0505","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1158\/1538-7445.AM2019-4425","article-title":"Abstract 4425: FCN-437: A novel, potent and selective oral inhibitor of CDK4\/6 for the treatment of solid tumors","volume":"79","author":"Lin","year":"2019","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0510","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/cas.13957","article-title":"Preclinical characterization of SHR6390, a novel CDK 4\/6 inhibitor, in vitro and in human tumor xenograft models","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Science"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0515","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1006\/bbrc.1994.1742","article-title":"Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275","volume":"201","author":"Losiewicz","year":"1994","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0520","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcdb.2020.04.016","article-title":"Roles of CDK\/Cyclin complexes in transcription and pre-mRNA splicing: Cyclins L and CDK11 at the cross-roads of cell cycle and regulation of gene expression","volume":"107","author":"Loyer","year":"2020","journal-title":"Seminars in Cell & Developmental Biology"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0525","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1039\/C9MO90013F","article-title":"Correction: Long non-coding RNA SNHG17 is an unfavourable prognostic factor and promotes cell proliferation by epigenetically silencing P57 in colorectal cancer","volume":"16","author":"Ma","year":"2020","journal-title":"Molecular Omics"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0530","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acsmedchemlett.6b00022","article-title":"2,8-Disubstituted-1,6-naphthyridines and 4,6-disubstituted-isoquinolines with potent, selective affinity for CDK8\/19","volume":"7","author":"Mallinger","year":"2016","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0535","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biology"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0540","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0545","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nsmb.2707","article-title":"Cks confers specificity to phosphorylation-dependent CDK signaling pathways","volume":"20","author":"McGrath","year":"2013","journal-title":"Nature Structural & Molecular Biology"},{"issue":"15","key":"10.1016\/bs.apcsb.2022.11.008_bb987","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.15252\/embj.201796905","article-title":"Structural basis of divergent cyclin-dependent kinase activation by Spy1\/RINGO proteins","volume":"36","author":"McGrath","year":"2017","journal-title":"The EMBO Journal"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0550","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/cells10061430","article-title":"The AMPK\/p27Kip1 pathway as a novel target to promote autophagy and resilience in aged cells","volume":"10","author":"McKay","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/bs.apcsb.2022.11.008_bb0555","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/bjc.2017.288","article-title":"Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies","volume":"117","author":"Mita","year":"2017","journal-title":"British Journal of Cancer"},{"issue":"20","key":"10.1016\/bs.apcsb.2022.11.008_bb0560","doi-asserted-by":"crossref","first-page":"E3654","DOI":"10.3390\/molecules24203654","article-title":"Stapled peptides\u2014A useful improvement for peptide-based drugs","volume":"24","author":"Moiola","year":"2019","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0565","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrneph.2016.168","article-title":"The epigenetic landscape of renal cancer","volume":"13","author":"Morris","year":"2017","journal-title":"Nature Reviews. Nephrology"},{"issue":"10","key":"10.1016\/bs.apcsb.2022.11.008_bb0570","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1541-7786.MCR-15-0474","article-title":"Bone marrow microenvironment niche regulates miR-221\/222 in acute lymphoblastic leukemia","volume":"14","author":"Moses","year":"2016","journal-title":"Molecular Cancer Research: MCR"},{"issue":"30","key":"10.1016\/bs.apcsb.2022.11.008_bb0575","doi-asserted-by":"crossref","first-page":"29694","DOI":"10.18632\/oncotarget.5088","article-title":"Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1\/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types","volume":"6","author":"Moussa","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0580","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/cts.12802","article-title":"A phase I study of dinaciclib in combination with MK-2206 in patients with advanced pancreatic cancer","volume":"13","author":"Murphy","year":"2020","journal-title":"Clinical and Translational Science"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0585","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2174\/1871520621666210908101751","article-title":"Naturally sourced CDK inhibitors and current trends in structure-based synthetic anticancer drug design by crystallography","volume":"22","author":"Nandi","year":"2022","journal-title":"Anti-Cancer Agents in Medicinal Chemistry"},{"issue":"8","key":"10.1016\/bs.apcsb.2022.11.008_bb0590","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/15384101.2021.1909261","article-title":"A cyclin D-CDK6 dimer helps to reshuffle cyclin-dependent kinase inhibitors (CKI) to overcome TGF-beta-mediated arrest and maintain CDK2 activity","volume":"20","author":"Nataraj","year":"2021","journal-title":"Cell Cycle (Georgetown, Texas)"},{"issue":"11","key":"10.1016\/bs.apcsb.2022.11.008_bb0595","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/ijc.33054","article-title":"The role of CDK6 in cancer","volume":"147","author":"Nebenfuehr","year":"2020","journal-title":"International Journal of Cancer"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0600","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/183590","article-title":"Tumor suppressor inactivation in the pathogenesis of adult T-cell leukemia","volume":"2015","author":"Nicot","year":"2015","journal-title":"Journal of Oncology"},{"issue":"7","key":"10.1016\/bs.apcsb.2022.11.008_bb0605","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbamcr.2014.03.026","article-title":"CDK5-mediated phosphorylation of p19INK4d avoids DNA damage-induced neurodegeneration in mouse hippocampus and prevents loss of cognitive functions","volume":"1843","author":"Ogara","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0610","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.critrevonc.2014.05.011","article-title":"microRNA and non-canonical TGF-\u03b2 signalling: Implications for prostate cancer therapy","volume":"92","author":"Ottley","year":"2014","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0615","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0620","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1060028018795146","article-title":"Abemaciclib: The newest CDK4\/6 inhibitor for the treatment of breast cancer","volume":"53","author":"Palumbo","year":"2019","journal-title":"The Annals of Pharmacotherapy"},{"issue":"8","key":"10.1016\/bs.apcsb.2022.11.008_bb0625","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"issue":"15","key":"10.1016\/bs.apcsb.2022.11.008_bb0630","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1128\/MCB.24.15.6653-6664.2004","article-title":"Genetic evidence for functional dependency of p18Ink4c on Cdk 4","volume":"24","author":"Pei","year":"2004","journal-title":"Molecular and Cellular Biology"},{"issue":"7572","key":"10.1016\/bs.apcsb.2022.11.008_bb0635","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature14904","article-title":"Mediator kinase inhibition further activates super-enhancer-associated genes in AML","volume":"526","author":"Pelish","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099956","article-title":"RPLP1, a crucial ribosomal protein for embryonic development of the nervous system","volume":"9","author":"Perucho","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0645","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1530\/ERC-13-0482","article-title":"Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: Natural history and function of menin in tumorigenesis","volume":"21","author":"Pieterman","year":"2014","journal-title":"Endocrine-Related Cancer"},{"issue":"9","key":"10.1016\/bs.apcsb.2022.11.008_bb985","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239315","article-title":"Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models","volume":"15","author":"Pinto","year":"2020","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0650","doi-asserted-by":"crossref","first-page":"E1983","DOI":"10.3390\/cancers11121983","article-title":"p53-mediated tumor suppression: DNA-damage response and alternative mechanisms","volume":"11","author":"Pitolli","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0655","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13058-020-01318-2","article-title":"MDM2 inhibition in combination with endocrine therapy and CDK4\/6 inhibition for the treatment of ER-positive breast cancer","volume":"22","author":"Portman","year":"2020","journal-title":"Breast Cancer Research: BCR"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0660","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12038-020-00099-2","article-title":"Evaluation of post-translational modifications in histone proteins: A review on histone modification defects in developmental and neurological disorders","volume":"45","author":"Ramazi","year":"2020","journal-title":"Journal of Biosciences"},{"issue":"Suppl 3","key":"10.1016\/bs.apcsb.2022.11.008_bb0665","first-page":"S489","volume":"13","author":"Richardson","year":"2017","journal-title":"Pharmacognosy Magazine"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0670","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/2472555220973602","article-title":"CDK family PROTAC profiling reveals distinct kinetic responses and cell cycle-dependent degradation of CDK2","volume":"26","author":"Riching","year":"2021","journal-title":"SLAS Discovery: Advancing Life Sciences R & D"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb986","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01675","article-title":"Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model","volume":"5","author":"Saisomboon","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0675","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/abr.abr_91_19","volume":"8","author":"Sanaei","year":"2019","journal-title":"Advanced Biomedical Research"},{"issue":"7","key":"10.1016\/bs.apcsb.2022.11.008_bb0680","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.31557\/APJCP.2020.21.7.2131","volume":"21","author":"Sanaei","year":"2020","journal-title":"Asian Pacific Journal of Cancer Prevention: APJCP"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0685","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/1735-5362.314824","article-title":"Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma","volume":"16","author":"Sanaei","year":"2021","journal-title":"Research in Pharmaceutical Sciences"},{"issue":"20","key":"10.1016\/bs.apcsb.2022.11.008_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126637","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019)","volume":"29","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0695","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4132\/jptm.2021.04.20","article-title":"Distinctive morphological and molecular features of urothelial carcinoma with an inverted growth pattern","volume":"55","author":"Sanguedolce","year":"2021","journal-title":"Journal of Pathology and Translational Medicine"},{"issue":"11","key":"10.1016\/bs.apcsb.2022.11.008_bb0700","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1134\/S0006297915110012","article-title":"Mechanisms of apoptosis","volume":"80","author":"Savitskaya","year":"2015","journal-title":"Biochemistry (Moscow)"},{"issue":"11","key":"10.1016\/bs.apcsb.2022.11.008_bb0705","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Reports"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0710","doi-asserted-by":"crossref","first-page":"E2045","DOI":"10.3390\/molecules22122045","article-title":"Regulation of G2\/M transition by inhibition of WEE1 and PKMYT1 kinases","volume":"22","author":"Schmidt","year":"2017","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0715","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Safety"},{"issue":"8","key":"10.1016\/bs.apcsb.2022.11.008_bb0720","doi-asserted-by":"crossref","first-page":"E1178","DOI":"10.3390\/cancers11081178","article-title":"P21 in cancer research","volume":"11","author":"Shamloo","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0725","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/jm301475f","article-title":"Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities","volume":"56","author":"Shao","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"issue":"10","key":"10.1016\/bs.apcsb.2022.11.008_bb0730","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/hepr.13353","article-title":"Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway","volume":"49","author":"Shen","year":"2019","journal-title":"Hepatology Research: The Official Journal of the Japan Society of Hepatology"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0735","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.582451","article-title":"CKS1B as drug resistance-inducing gene\u2014A potential target to improve cancer therapy","volume":"10","author":"Shi","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"9","key":"10.1016\/bs.apcsb.2022.11.008_bb0740","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","article-title":"From structure modification to drug launch: A systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy","volume":"65","author":"Shi","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0745","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s44160-021-00011-2","article-title":"Stereospecific \u03b1-(hetero)arylation of sulfoximines and sulfonimidamides","volume":"1","author":"Shultz","year":"2022","journal-title":"Nature Synthesis"},{"issue":"10","key":"10.1016\/bs.apcsb.2022.11.008_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115461","article-title":"New CDK8 inhibitors as potential anti-leukemic agents\u2014Design, synthesis and biological evaluation","volume":"28","author":"Solum","year":"2020","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"18","key":"10.1016\/bs.apcsb.2022.11.008_bb0755","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1158\/0008-5472.CAN-17-0072","article-title":"HDAC1 upregulation by NANOG promotes multidrug resistance and a stem-like phenotype in immune edited tumor cells","volume":"77","author":"Song","year":"2017","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0760","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1535-7163.MCT-08-0890","article-title":"Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines","volume":"8","author":"Squires","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb982","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1242\/dmm.027441","article-title":"MicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications","volume":"10","author":"Strubberg","year":"2017","journal-title":"Disease Models & Mechanisms"},{"issue":"6\u20137","key":"10.1016\/bs.apcsb.2022.11.008_bb0765","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1387\/ijdb.160343LB","article-title":"States of G0 and the proliferation-quiescence decision in cells, tissues and during development","volume":"61","author":"Sun","year":"2017","journal-title":"The International Journal of Developmental Biology"},{"issue":"1\u20132","key":"10.1016\/bs.apcsb.2022.11.008_bb0770","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11010-016-2693-2","article-title":"Phosphatases and kinases regulating CDC25 activity in the cell cycle: Clinical implications of CDC25 overexpression and potential treatment strategies","volume":"416","author":"Sur","year":"2016","journal-title":"Molecular and Cellular Biochemistry"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0775","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/imb.12381","article-title":"Bombyx mori cyclin-dependent kinase inhibitor is involved in regulation of the silkworm cell cycle","volume":"27","author":"Tang","year":"2018","journal-title":"Insect Molecular Biology"},{"issue":"14","key":"10.1016\/bs.apcsb.2022.11.008_bb0780","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1093\/nar\/gkaa514","article-title":"CDK12 globally stimulates RNA polymerase II transcription elongation and carboxyl-terminal domain phosphorylation","volume":"48","author":"Tellier","year":"2020","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0785","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/dmr-21-21","article-title":"Targeted therapy for pancreatic cancer: Lessons learned and future opportunities","volume":"4","author":"Thomas","year":"2021","journal-title":"Digestive Medicine Research"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0790","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","article-title":"Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein's C-terminal helix","volume":"74","author":"Topacio","year":"2019","journal-title":"Molecular Cell"},{"issue":"12","key":"10.1016\/bs.apcsb.2022.11.008_bb0795","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00106-019-00766-3","article-title":"Update on HPV-associated head and neck cancer-highlights from the 2019 ASCO Annual Meeting","volume":"67","author":"Tribius","year":"2019","journal-title":"HNO"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0800","doi-asserted-by":"crossref","first-page":"E945","DOI":"10.3390\/ijms17060945","article-title":"Potential diagnostic, prognostic and therapeutic targets of microRNAs in human gastric cancer","volume":"17","author":"Tsai","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0805","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-62703-748-8_2","article-title":"The role of microRNAs in biological processes","volume":"1107","author":"T\u00fcfekci","year":"2014","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0810","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/09537104.2019.1667497","article-title":"Megakaryocyte polyploidization: Role in platelet production","volume":"31","author":"Vainchenker","year":"2020","journal-title":"Platelets"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0815","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1039\/C5SC02311D","article-title":"Effect of lipid peroxidation on membrane permeability of cancer and normal cells subjected to oxidative stress","volume":"7","author":"Van der Paal","year":"2016","journal-title":"Chemical Science"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0820","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/srep14798","article-title":"The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1","volume":"5","author":"Voets","year":"2015","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0825","doi-asserted-by":"crossref","first-page":"375","DOI":"10.18632\/oncotarget.1568","article-title":"A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine","volume":"5","author":"Walsby","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0830","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/cei.12907","article-title":"Critical roles of conventional dendritic cells in promoting T cell-dependent hepatitis through regulating natural killer T cells","volume":"188","author":"Wang","year":"2017","journal-title":"Clinical and Experimental Immunology"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0835","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.yexmp.2016.05.001","article-title":"Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis","volume":"100","author":"Wang","year":"2016","journal-title":"Experimental and Molecular Pathology"},{"issue":"8","key":"10.1016\/bs.apcsb.2022.11.008_bb0840","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1002\/jcp.27989","article-title":"MicroRNA-16-5p enhances radiosensitivity through modulating Cyclin D1\/E1-pRb-E2F1 pathway in prostate cancer cells","volume":"234","author":"Wang","year":"2019","journal-title":"Journal of Cellular Physiology"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0845","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/gutjnl-2019-318506","article-title":"CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0850","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","article-title":"CDK7-dependent transcriptional addiction in triple-negative breast cancer","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0855","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","article-title":"Discovery of 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute myelocytic leukemia","volume":"61","author":"Wang","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"10","key":"10.1016\/bs.apcsb.2022.11.008_bb0860","first-page":"729","article-title":"Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia","volume":"23","author":"Wang","year":"2018","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"17","key":"10.1016\/bs.apcsb.2022.11.008_bb0865","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.3390\/cancers13174389","article-title":"Cyclin dependent kinase-1 (CDK-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC)","volume":"13","author":"Wijnen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0870","doi-asserted-by":"crossref","DOI":"10.1177\/1177271919846454","article-title":"Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia","volume":"14","author":"Wong","year":"2019","journal-title":"Biomarker Insights"},{"issue":"14","key":"10.1016\/bs.apcsb.2022.11.008_bb0875","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.7150\/thno.25487","article-title":"Blocking CDK1\/PDK1\/\u03b2-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma","volume":"8","author":"Wu","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0880","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbrc.2019.04.014","article-title":"Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer","volume":"513","author":"Xi","year":"2019","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0885","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41467-021-22327-5","article-title":"Dominant role of CDKN2B\/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis","volume":"12","author":"Xia","year":"2021","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/bs.apcsb.2022.11.008_bb0890","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4252\/wjsc.v12.i6.481","article-title":"Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy","volume":"12","author":"Xiao","year":"2020","journal-title":"World Journal of Stem Cells"},{"issue":"1","key":"10.1016\/bs.apcsb.2022.11.008_bb0895","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2014.02.105","article-title":"Dux4 induces cell cycle arrest at G1 phase through upregulation of p21 expression","volume":"446","author":"Xu","year":"2014","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"11","key":"10.1016\/bs.apcsb.2022.11.008_bb0900","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.bmcl.2015.03.066","article-title":"Discovery of novel indirubin-3\u2019-monoxime derivatives as potent inhibitors against CDK2 and CDK9","volume":"25","author":"Yan","year":"2015","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0905","article-title":"Pharmacological properties of indirubin and its derivatives","volume":"151","author":"Yang","year":"2022","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0910","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.757137","article-title":"MHC-II signature correlates with anti-tumor immunity and predicts anti-PD-L1 response of bladder cancer","volume":"10","author":"Yi","year":"2022","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"10","key":"10.1016\/bs.apcsb.2022.11.008_bb0915","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41419-021-04260-z","article-title":"The FOXM1\/RNF26\/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer","volume":"12","author":"Yi","year":"2021","journal-title":"Cell Death & Disease"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0920","doi-asserted-by":"crossref","first-page":"9593254","DOI":"10.1155\/2020\/9593254","article-title":"Hepigenetics: A review of epigenetic modulators and potential therapies in hepatocellular carcinoma","volume":"2020","author":"Yousef","year":"2020","journal-title":"BioMed Research International"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113391","article-title":"Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation","volume":"218","author":"Yu","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1016\/bs.apcsb.2022.11.008_bb0930","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1172\/JCI76507","article-title":"Targeted p16(Ink4a) epimutation causes tumorigenesis and reduces survival in mice","volume":"124","author":"Yu","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"issue":"4","key":"10.1016\/bs.apcsb.2022.11.008_bb0935","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.chom.2015.10.001","article-title":"Cell-cycle regulators and cell death in immunity","volume":"18","author":"Zebell","year":"2015","journal-title":"Cell Host & Microbe"},{"issue":"7686","key":"10.1016\/bs.apcsb.2022.11.008_bb0940","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0945","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.biopha.2015.02.005","article-title":"MiR-25 promotes glioma cell proliferation by targeting CDKN1C","volume":"71","author":"Zhang","year":"2015","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"10","key":"10.1016\/bs.apcsb.2022.11.008_bb0950","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","article-title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors","volume":"12","author":"Zhang","year":"2016","journal-title":"Nature Chemical Biology"},{"issue":"5","key":"10.1016\/bs.apcsb.2022.11.008_bb0955","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"American Journal of Cancer Research"},{"issue":"18","key":"10.1016\/bs.apcsb.2022.11.008_bb0960","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1039\/C9CC00163H","article-title":"PROTACs suppression of CDK4\/6, crucial kinases for cell cycle regulation in cancer","volume":"55","author":"Zhao","year":"2019","journal-title":"Chemical Communications (Cambridge, England)"},{"issue":"24","key":"10.1016\/bs.apcsb.2022.11.008_bb0965","doi-asserted-by":"crossref","first-page":"12704","DOI":"10.18632\/oncotarget.2871","article-title":"Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy","volume":"5","author":"Zhao","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/bs.apcsb.2022.11.008_bb0970","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/cells11020279","article-title":"Cyclin-dependent kinases and CTD phosphatases in cell cycle transcriptional control: conservation across eukaryotic kingdoms and uniqueness to plants","volume":"11","author":"Zheng","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/bs.apcsb.2022.11.008_bb0975","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12447","article-title":"Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1\/Cip1 and p19INK4d upregulation in hepatocellular carcinoma","volume":"51","author":"Zhou","year":"2018","journal-title":"Cell Proliferation"},{"key":"10.1016\/bs.apcsb.2022.11.008_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111952","article-title":"Development of selective mono or dual PROTAC degrader probe of CDK isoforms","volume":"187","author":"Zhou","year":"2020","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"34","key":"10.1016\/bs.apcsb.2022.11.008_bb983","doi-asserted-by":"crossref","first-page":"23505","DOI":"10.18632\/oncotarget.25239","article-title":"The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells","volume":"9","author":"Zocchi","year":"2018","journal-title":"Oncotarget"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Control of Cell Cycle & Cell Proliferation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162322000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162322000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T18:26:46Z","timestamp":1728844006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162322000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443158223"],"references-count":202,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2022.11.008","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}